Attached files
file | filename |
---|---|
EX-99.1 - CORPORATE PRESENTATION - AzurRx BioPharma, Inc. | ex99-1.htm |
EX-99.2 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): November 27,
2017
AZURRX BIOPHARMA, INC.
Delaware
|
001-37853
|
46-4993860
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
760
Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York
|
|
11226
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [
]
Item 7.01
Regulation FD Disclosure
The Company has updated
its corporate presentation, a copy of which is furnished as Exhibit
99.1 to this Current Report on Form 8-K. A copy of the investor
presentation is also available on the Company’s website
located at
www.azurrx.com.
On December 1,
2017, we issued a press release announcing that
we will be presenting at
the 10th
Annual LD
Micro Main Event on Tuesday, December 5th at
1:30 PM PT/4:30 PM ET. A copy of the press release is
furnished as Exhibit 99.2 and is incorporated by reference
herein.
In accordance with
General Instruction B.2 of Form 8-K, the information furnished
pursuant to this Item
7.01, and including
Exhibits 99.1 and 99.2 furnished herewith,
shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange
Act”), nor shall it
be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a
filing.
Item 8.01
Other Events
On
November 27, 2017, the Company delivered a notice to Lincoln Park
Capital Fund, LLC (“Lincoln
Park”) to extend the maturity date of a Senior Secured
Original Issue Discount Convertible Debenture (the “Debenture”)
issued to Lincoln Park on April 11, 2017, to July 11, 2018 (the
“Notice”). The
Notice was delivered pursuant to the terms of the Debenture, as
modified on November 10, 2017.
Item 9.01
Financial Statements and Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AzurRx BioPharma,
Inc.
|
|
|
|
|
|
|
Date:
December 1, 2017
|
By:
|
/s/
Johan
M. Spoor
|
|
|
|
Name:
Johan M. Spoor
|
|
|
|
Title:
Chief Executive Officer
|
|
Exhibit Index
Exhibit Number
|
|
Description
|
|
|
|
|
Corporate Presentation, dated December 2017
|
|
|
Press Release, dated December 1, 2017
|